Alnylam Pharmaceuticals Cambridge. Receive news and updates on the work at Alnylam that affects you most. Contact Us.
The following content may not be associated with Alnylam Pharmaceuticals.
Since 2002, Dr. John Maraganore has served as the CEO and a Director of Alnylam. John Maraganore, P h D Chief Executive Officer. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Alnylam to Webcast Presentations at Upcoming May Investor Conferences: May 06, 2020: Alnylam Pharmaceuticals Reports First Quarter 2020 Financial Results and Highlights Recent Period Activity: May 04, 2020: Vir and Alnylam Identify RNAi Therapeutic Development Candidate, VIR-2703 (ALN-COV), Targeting SARS-CoV-2 for the Treatment of COVID-19
675 West Kendall St Cambridge, MA 02142 Tel: 617.551.8200 Fax: 617.551.8101.
Prior to Alnylam, Dr. Maraganore served as an officer and a member of the management team for Millennium Pharmaceuticals, Inc. For inquiries or to request additional information, we can be reached by email or calling our corporate headquarters. SIGN UP FOR EMAIL UPDATES. ... Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals. Alnylam Pharmaceuticals Email Format Alnylam Pharmaceuticals uses 6 email formats, with … Alnylam is leading the translation of RNA interference (RNAi) into an innovative new class of medicines for patients who have limited or inadequate treatment options.
Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals…
For inquiries or to request additional information, Alnylam can be reached by email or by calling the company's corporate headquarters.
Links to all outside sites are provided as a reference for our visitors.
Proceed to Site × Learn about Alnylam Pharmaceuticals, RNAi therapeutics, and the company's efforts in treating amyloidosis, hyperoxaluria, and porphyria. Kärntner Ring 5-7
Alnylam team members only communicate with potential candidates through an official Alnylam email address ending in “@alnylam.com.” Please do not provide any personal information if you receive a suspicious inquiry or job offer.
Alnylam Austria GmbH.